For more information, see the GeneReviews Copyright Notice and Usage Disclaimer.
For questions regarding permissions: admasst/at/uw.edu.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2013.
Disease characteristics. Sotos syndrome is characterized by the cardinal features of typical facial appearance, overgrowth (height and/or head circumference ≥2 SD above the mean), and learning disability ranging from mild (children attend mainstream schools and are likely to be independent as adults) to severe (lifelong care and support will likely be required). Sotos syndrome is associated with the major features of behavioral problems, congenital cardiac anomalies, neonatal jaundice, renal anomalies, scoliosis, and seizures.
Diagnosis/testing. The diagnosis of Sotos syndrome is established by a combination of clinical findings and molecular genetic testing. NSD1 is the only gene in which mutations are known to cause Sotos syndrome. About 80%-90% of individuals with Sotos syndrome have a demonstrable NSD1 abnormality.
Management. Treatment of manifestations: Referral to appropriate specialists for management of learning disability/speech delays, behavior problems, cardiac abnormalities, renal anomalies, scoliosis, seizures; no intervention if MRI shows ventricular dilatation without raised intracranial pressure.
Surveillance: Regular review by a general pediatrician for younger children, individuals with many medical complications, and families requiring more support than average; less frequent review of older children/teenagers and those individuals without many medical complications.
Other: Education of affected individuals and their families regarding natural history, treatment, mode of inheritance, genetic risks to other family members, and consumer-oriented resources; genetic counseling of young adults regarding risk to offspring.
Genetic counseling. Sotos syndrome is inherited in an autosomal dominant manner. More than 95% of individuals have a de novo mutation. If neither parent of a proband has Sotos syndrome, the risk to sibs of the proband is low (<1%). The risk to offspring of affected individuals is 50%. Prenatal testing is possible for pregnancies at risk if the NSD1 disease-causing mutation has been identified in an affected family member.
The clinical diagnosis of Sotos syndrome can be made if an individual has a characteristic facial gestalt, a learning disability, and overgrowth [Rio et al 2003, Turkmen et al 2003, Cecconi et al 2005, Faravelli 2005, Tatton-Brown et al 2005b, Waggoner et al 2005]. Based on the analysis of more than 500 individuals with an NSD1 abnormality, these three cardinal features were shown to occur in at least 90% of affected individuals [Tatton-Brown et al 2005b]. Where an individual does not fulfill all three clinical criteria, the clinical suspicion of Sotos syndrome can be confirmed with genetic testing (see Molecular Genetic Testing).
Cytogenetic testing. Most affected individuals do not have a cytogenetic abnormality. Rarely, a cytogenetic abnormality such as a translocation involving 5q35 results in Sotos syndrome [Kurotaki et al 2002].
Gene. NSD1 is the only gene in which mutations are currently known to cause Sotos syndrome.
Clinical testing
Table 1. Summary of Molecular Genetic Testing Used in Sotos Syndrome
| Gene Symbol | Test Method | Mutations Detected | Mutation Detection Frequency by Test Method 1 | Test Availability | |
|---|---|---|---|---|---|
| Japanese | Non-Japanese | ||||
| NSD1 | Sequence analysis / mutation scanning 2 | Sequence variants 3 | ~12% 4 | 27%-93% 5 | Clinical |
| Deletion / duplication analysis 6 | 5q35 microdeletion encompassing NSD1 and NSD1 partial-gene deletions | ~50% 7, 8, 9 | ~15% 8, 9 | ||
| FISH | 5q35 microdeletion encompassing NSD1 | ~50% 4, 8, 10 | ~10% 5, 8, 10 | ||
1. The ability of the test method used to detect a mutation that is present in the indicated gene
2. Sequence analysis and mutation scanning of the entire gene can have similar mutation detection frequencies; however, mutation detection rates for mutation scanning may vary considerably among laboratories depending on the specific protocol used.
3. Examples of mutations detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site mutations.
4. Limited mutation screening has been undertaken in Japanese individuals [Kurotaki et al 2003, Miyake et al 2003, Tei et al 2006].
5. The variability in detection rate reflects different eligibility criteria for screening [Douglas et al 2003, Rio et al 2003, Cecconi et al 2005, Faravelli 2005, Melchior et al 2005, Waggoner et al 2005, Saugier-Veber et al 2007]. An NSD1 detection rate of at least 90% was achieved when the clinical diagnosis of Sotos syndrome had been made by clinicians with expertise in the condition [Turkmen et al 2003, Tatton-Brown et al 2005b].
6. Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; a variety of methods including quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), or targeted array GH (gene/segment-specific) may be used. A full array GH analysis that detects deletions/duplications across the genome may also include this gene/segment.
7. The contribution of partial-gene deletions to Sotos syndrome in Japanese individuals is currently unknown [Douglas et al 2005, Tatton-Brown et al 2005b].
8. The microdeletions can be detected with equal sensitivity by FISH or other deletion/duplication analytic methods (e.g., multiplex ligation-dependent probe amplification [MLPA]) [Douglas et al 2003, Kurotaki et al 2003, Rio et al 2003, Turkmen et al 2003, Cecconi et al 2005, Tatton-Brown et al 2005a, Visser et al 2005, Waggoner et al 2005].
9. Exonic/multiexonic deletions (i.e., deletion of one or more exons) are responsible for an estimated 5% of Sotos syndrome [Douglas et al 2005, Tatton-Brown et al 2005b]. Deletion/duplication analytic methods (see footnote 6) are required; typically, FISH cannot detect exonic/multiexonic gene deletions. Deletions encompassing exons 1 and 2 are most common, likely reflecting the high density of Alu repeats in the flanking sequences [Douglas et al 2005].
10. Typically, FISH cannot detect exonic/multiexonic gene deletions.
Interpretation of test results. All frameshift and nonsense mutations, splicing variants at consensus residues, partial-gene deletions, and microdeletions encompassing NSD1 are predicted to be pathogenic.
Missense variants require more careful interpretation.
For issues to consider in interpretation of sequence analysis results, click here.
Information on specific allelic variants may be available in Molecular Genetics (see Table A. Genes and Databases and/or Pathologic allelic variants).
To confirm/establish the diagnosis in a proband
Prenatal diagnosis and preimplantation genetic diagnosis (PGD) for at-risk pregnancies require prior identification of the disease-causing mutation in the family.
NSD1 abnormalities have high specificity and sensitivity for Sotos syndrome. Molecular genetic testing failed to identify mutations in NSD1 in more than 500 individuals with clinical diagnoses other than Sotos syndrome, including Marshall-Smith syndrome, autosomal dominant macrocephaly, nonspecific overgrowth, and individuals with macrocephaly in association with autism spectrum disorders [Turkmen et al 2003, Tatton-Brown et al 2005b, Waggoner et al 2005, Buxbaum et al 2007].
In rare cases, other clinical conditions that show overlap with Sotos syndrome and involve NSD1 mutations have been reported:
Based on a review of 230 persons with NSD1 abnormalities, the clinical features of Sotos syndrome were classified as cardinal features (occurring in at least 90% of affected individuals), major features (occurring in 15%-89%), and associated features (occurring in ≥2% and <15% of persons) [Tatton-Brown et al 2005b].
It is very likely that additional associated features will be recognized as new cases are identified. It is also possible that some associated features (e.g., constipation) occur with greater frequency than appreciated now and thus could be reclassified as major features in the future.
Cardinal Features (present in ≥90% of persons with Sotos syndrome)
Major Features (present in 15%-89% of persons with Sotos syndrome)
Characteristic facial appearance. The facial gestalt of Sotos syndrome is evident at birth, but becomes most recognizable between ages one and six years. The head is dolichocephalic and the forehead broad and prominent. Often the hair in the frontotemporal region is sparse. The palpebral fissures are usually downslanting. Malar flushing may be present. At birth, the mandible appears small, but by childhood it is pointed, and in adulthood, often prominent and square [Allanson & Cole 1996, Tatton-Brown & Rahman 2004].
Learning disability. The majority of individuals with Sotos syndrome have some degree of intellectual impairment. The spectrum is broad and ranges from mild learning disability (affected individuals would be expected to live independently and have their own families) to severe learning disability (affected individuals would be unlikely to live independently as adults). It has been suggested that children with Sotos syndrome have difficulties with speech and language, particularly expressive language and articulation [Ball et al 2005]. The majority have mild-moderate learning disability; the level of intellectual impairment generally remains stable throughout life [Tatton-Brown et al 2005b; Authors, unpublished data].
Growth. Sotos syndrome is associated with overgrowth of prenatal onset. Delivery is typically at term. The average birth length approximates to the 98th centile and the average birth head circumference is between the 91st and 98th centiles. Average birth weight is within the normal range (between the 50th and 91st centile).
Before age ten years, affected children demonstrate rapid linear growth. They are often described as being considerably taller than their peers. Height and/or head circumference are generally 2 SD or more above the mean. However, growth is also influenced by parental heights and some individuals do not have growth parameters above the 98th centile [Cole & Hughes 1994, Tatton-Brown et al 2005b].
Data on final adult height are scarce; however, in both men and women, the range of final adult height is broad [Agwu et al 1999; Tatton-Brown & Rahman, unpublished data].
The de Boer et al [2005] study of auxologic data supports that of Agwu et al [1999] and shows that individuals with NSD1 mutations have an increased arm span/height ratio, decreased sitting/standing height ratio, and increased hand length. These data suggest that the increased height in Sotos syndrome is predominantly the result of an increase in limb length [Agwu et al 1999, de Boer et al 2005].
Behavioral problems. A wide range of behavioral problems are common at all ages: autistic spectrum disorder, phobias, and aggression have been described [Tatton-Brown, personal communication]. Often difficulty with peer group relationships is precipitated by large size, naiveté, and lack of awareness of social cues [Finegan et al 1994]. These observations were confirmed in a study of individuals with a clinical diagnosis of Sotos syndrome (some with and some without an NSD1 mutation); it was additionally noted that attention-deficit hyperactivity disorder (ADHD) is not common among individuals with Sotos syndrome [de Boer et al 2006]
Bone age. Bone age often reflects the accelerated growth velocity and is advanced in 75%-80% of prepubertal children. However, bone age interpretation is influenced by the "threshold" taken as significant, the method of assessment, subjective interpretative error, and the age at which the assessment is made.
Cardiac abnormalities. About 20% of individuals have cardiac anomalies that range in severity from single, often self-limiting anomalies including PDA, ASD, and VSD to more severe, complex cardiac abnormalities. Recently two unrelated individuals with Sotos syndrome were shown to have left ventricular non-compaction [Martinez et al 2011]. Only a minority of the cardiac abnormalities associated with Sotos syndrome require surgical intervention.
Cranial MRI/CT abnormalities are identified in the majority of individuals with Sotos syndrome and an NSD1 mutation. Ventricular dilatation (particularly in the trigone region) is most frequently identified, but other abnormalities include midline changes (hypoplasia or agenesis of the corpus callosum, mega cisterna magna, cavum septum pellucidum), cerebral atrophy, and small cerebellar vermis [Waggoner et al 2005].
Dental abnormalities. Premature dental eruption and poor dental quality have been reported [Cole & Hughes 1994, Leventopoulos et al 2009].
Joint hyperlaxity/pes planus. Joint laxity is reported in at least 20% of individuals with Sotos syndrome.
Pregnancy. Complications in pregnancy may occur. In particular, maternal preeclampsia occurs in about 15% of pregnancies of children with Sotos syndrome.
Neonatal complications. Neonates may have jaundice (~65%), hypotonia (~75%), and poor feeding (~70%). These complications tend to resolve spontaneously, but in a small minority intervention is required.
Renal abnormalities. About 15% of individuals with an NSD1 mutation have a renal abnormality; vesicoureteric reflux is the most common. Some individuals may have quiescent vesicoureteric reflux and may present in adulthood with renal impairment.
Scoliosis. Present in about 30% of affected individuals, scoliosis is only rarely severe enough to require bracing or surgery.
Seizures. Approximately 25% of individuals with Sotos syndrome develop non-febrile seizures at some point in their lives and some require ongoing therapy. Absence, tonic-clonic, myoclonic, and partial complex seizures have all been reported.
Other
Tumors. Tumors occur in approximately 3% of persons with Sotos syndrome and include sacrococcygeal teratoma, neuroblastoma, presacral ganglioma, acute lymphoblastic leukemia (ALL) and small cell lung cancer [Hersh et al 1992, Tatton-Brown & Rahman 2004]. De Boer and colleagues have characterized and reviewed these problems and compared persons with Sotos syndrome who have NSD1 mutations to those who do not [de Boer et al 2006].
Various other clinical features have been associated with Sotos syndrome. Some associated features, such as constipation and hearing problems caused by chronic otitis media, are common. If future studies show that some associated features occur in more than 15% of individuals with Sotos syndrome and therefore at higher frequencies than in the general population, these features may be secondary to disruption of NSD1 rather than incidental findings. The following features are seen in 2%-15% of individuals with Sotos syndrome [Tatton-Brown et al 2005b]:
Through evaluation of 234 individuals with Sotos syndrome with an NSD1 abnormality, it has been shown that, in general, individuals with a 5q35 microdeletion have less overgrowth and more severe learning disability than individuals with an intragenic mutation [Tatton-Brown et al 2005b].
Genotype-phenotype correlations are not evident between intragenic mutations and 5q35 microdeletions for other clinical features associated with Sotos syndrome (i.e., cardiac abnormalities, renal anomalies, seizures, scoliosis). In addition, no correlations were observed between type of intragenic mutation (missense vs truncating) and phenotype or between position of mutation (5' vs 3') and phenotype [Tatton-Brown et al 2005b].
More than 100 parental samples have been screened [Douglas et al 2003, Rio et al 2003, Turkmen et al 2003, Tatton-Brown et al 2005b]. To date, no NSD1 mutations/deletions have been identified in an unaffected parent or unaffected sib of a child with NSD1-positive Sotos syndrome. Thus, Sotos syndrome appears to be a fully penetrant condition.
Of note, expressivity is highly variable. Individuals with the same mutation, even within the same family, can be affected differently [Tatton-Brown et al 2005b].
Anticipation has not been reported in Sotos syndrome.
Sotos syndrome takes its name from Juan Sotos, who reported five children with overgrowth, learning disability, and a characteristic facial appearance in 1964.
Sotos syndrome is estimated to occur in 1:14,000 live births [Rahman, unpublished data].
Overgrowth conditions that may be confused with Sotos syndrome:
Note to clinicians: For a patient-specific ‘simultaneous consult’ related to this disorder, go to
, an interactive diagnostic decision support software tool that provides differential diagnoses based on patient findings (registration or institutional access required).
To establish the extent of disease in an individual diagnosed with Sotos syndrome, the following evaluations are recommended [Tatton-Brown & Rahman 2007]:
When clinical problems (e.g., cardiac abnormalities, seizures, renal problems, scoliosis) or difficulties with learning/behavior/speech are identified, referral to the appropriate specialist is recommended.
If MRI has been performed and ventricular dilatation demonstrated, shunting should not usually be necessary as the "arrested hydrocephalus" associated with Sotos syndrome is typically non-obstructive and not associated with raised intracranial pressure. If raised intracranial pressure is suspected, investigation and management in consultation with neurologists and neurosurgeons would be appropriate.
Some children in North America have been prescribed Ritalin® with varying success; in Europe, behavioral management strategies are more commonly used, again with varying success.
Antibiotic prophylaxis is indicated in individuals with proven vesicoureteric reflux.
Regular review (by a general pediatrician) is recommended for younger children, individuals with many medical complications needing coordination of medical specialists, and families requiring more support than average [Tatton-Brown & Rahman 2007].
The clinician may wish to review less frequently older children/teenagers and those individuals without many medical complications.
The following are appropriate at the clinical review:
Note: Cancer screening is not recommended. (1) The absolute risk of sacrococcygeal teratoma and neuroblastoma is low (~1%) [Tatton-Brown et al 2005b, Tatton-Brown & Rahman 2007]. This level of risk does not warrant routine screening, particularly as screening for neuroblastoma has not been shown to decrease mortality and can lead to false positive results [Schilling et al 2002]. (2) Wilms tumor risk is not significantly increased and routine renal ultrasound examination is not indicated [Scott et al 2006].
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.
Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. —ED.
Sotos syndrome is inherited in an autosomal dominant manner.
Parents of a proband
Sibs of a proband
Offspring of a proband
Other family members of a proband
Considerations in families with an apparent de novo mutation. When neither parent of a proband with an autosomal dominant condition has the pathogenic mutation or clinical evidence of the disorder, it is extremely likely that the proband has a de novo mutation. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.
Family planning
DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, mutations, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.
Molecular genetic testing. If the disease-causing mutation has been identified in the family, prenatal diagnosis for pregnancies at increased risk is possible by analysis of DNA extracted from fetal cells obtained by amniocentesis (usually performed at ~15-18 weeks’ gestation) or chorionic villus sampling (usually performed at ~10-12 weeks’ gestation).
Ultrasound examination. Prenatal diagnosis cannot be accurately accomplished by ultrasound examination: the features of Sotos syndrome likely to be detected by ultrasound examination, such as macrocephaly and increased length, are nonspecific.
Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.
Preimplantation genetic diagnosis (PGD) may be an option for some families in which the disease-causing mutation has been identified.
GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.
Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.
Table A. Sotos Syndrome: Genes and Databases
| Gene Symbol | Chromosomal Locus | Protein Name | Locus Specific | HGMD |
|---|---|---|---|---|
| NSD1 | 5q35 | Histone-lysine N-methyltransferase, H3 lysine-36 and H4 lysine-20 specific | Nuclear receptor binding SET Domain protein 1 (NSD1) @ LOVD | NSD1 |
Table B. OMIM Entries for Sotos Syndrome (View All in OMIM)
Normal allelic variants. NSD1 comprises 22 coding exons (NM_022455.4). Many normal variants have been identified [Douglas et al 2003, Kurotaki et al 2003, Rio et al 2003, Turkmen et al 2003, Tatton-Brown et al 2005b].
Pathologic allelic variants. More than 100 pathogenic allelic variants have been published. No mutational hot spots have been identified [Douglas et al 2003, Kurotaki et al 2003, Rio et al 2003, Turkmen et al 2003, Faravelli 2005, Tatton-Brown et al 2005b]. See Table A.
A recurrent 1.9-Mb 5q35 microdeletion encompassing NSD1 has been reported in most Japanese and some non-Japanese individuals with Sotos syndrome [Kurotaki et al 2003, Tatton-Brown et al 2005a, Tatton-Brown et al 2005b, Visser et al 2005]. The majority are generated by nonallelic homologous recombination between flanking low-copy repeats [Kurotaki et al 2003, Tatton-Brown et al 2005a, Visser et al 2005]. Many of these recurrent deletions have the same breakpoints, and a specific chromatin structure may increase recurrent crossover events and predispose to recombination hot spots at 5q35 [Visser et al 2005].
Normal gene product. Only limited data exist regarding the functions of histone-lysine N-methyltransferase, H3 lysine-36 and H4 lysine-20 specific (NSD1), a protein of 2696 amino acids. It is expressed in the brain, kidney, skeletal muscle, spleen, thymus, and lung. NSD1 contains at least 12 functional domains including two nuclear receptor interaction domains (NID-L and NID+L), two proline-tryptophan-tryptophan-proline (PWWP) domains, five plant homeo domains (PHD), and a SET (su(var)3-9, enhancer of zeste, trithorax) domain. The most distinctive of these domains are the SET and associated SAC (SET-associated Cys-rich) domains, which are found in histone methyltransferases that regulate chromatin states. The SET domain of NSD1 has unique histone specificity, methylating K36 on H3 and K20 on H4 [Rayasam et al 2003]. PHDs are also typically found in proteins that act at the chromatin level, and PWWP domains are implicated in protein-protein interactions and are often found in methyltransferases. The nuclear receptors of NSD1, NID-L, and NID+L are typical of those found in corepressors and coactivators [Huang et al 1998]. The presence of these distinctive domains suggests that NSD1 is a histone methyltransferase that acts as a transcriptional intermediary factor capable of both negatively and positively influencing transcription, depending on the cellular context [Kurotaki et al 2001].
Abnormal gene product. How functional abrogation of NSD1 results in Sotos syndrome is not currently known.
Medical Genetic Searches: A specialized PubMed search designed for clinicians that is located on the PubMed Clinical Queries page 
For more information, see the GeneReviews Copyright Notice and Usage Disclaimer.
For questions regarding permissions: admasst/at/uw.edu.
Your browsing activity is empty.
Activity recording is turned off.
See more...